Bluebird Bio Recieves Receipt Of Delinquency Notice From Nasdaq; The Notices Have No Immediate Effect On The Listing Or Trading Of The Company's Common Stock On The Nasdaq.

Benzinga · Aug 24 04:07

bluebird bio, Inc. (NASDAQ:BLUE) today announced that it received notices (the "notices") on August 20, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").

The notices have no immediate effect on the listing or trading of the Company's common stock on the Nasdaq.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Bluebird Bio Recieves Receipt Of Delinquency Notice From Nasdaq; The Notices Have No Immediate Effect On The Listing Or Trading Of The Company's Common Stock On The Nasdaq.

Risk Disclaimer